Advertisement

Ethnicity and Atrial Fibrillation: A Counterintuitive Phenomenon

  • Andrea Colella
  • Pietro Amedeo ModestiEmail author
Chapter
Part of the Updates in Hypertension and Cardiovascular Protection book series (UHCP)

Abstract

Atrial fibrillation, the arrhythmia most frequently encountered in clinical practice, is currently responsible for one third of all ischemic strokes. According to the Global Burden of Disease Study, the age-adjusted prevalence of AF is lower in low- and middle-income countries when compared to wealthy nations. Furthermore, despite the generally higher burden of most primary AF risk factors in ethnic minorities, epidemiology studies have consistently shown that AF prevalence is lower among individuals belonging to ethnic minorities than among individuals with European ancestry. The discordance between the higher AF risk factor burden and the lower incidence and prevalence of AF was seen as a “paradoxical relationship.”

Keywords

Atrial fibrillation Ethnic minorities Rheumatic heart disease Genome-wide association studies Screening Management of atrial fibrillation 

References

  1. 1.
    Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014;129:837–47.CrossRefGoogle Scholar
  2. 2.
    Friberg L, Bergfeldt L. Atrial fibrillation prevalence revisited. J Intern Med. 2013;274:461–8.CrossRefGoogle Scholar
  3. 3.
    Majeed A, Moser K, Carroll K. Trends in the prevalence and management of atrial fibrillation in general practice in England and Wales, 1994-1998: analysis of data from the general practice research database. Heart. 2001;86:284–8.CrossRefGoogle Scholar
  4. 4.
    Haim M, Hoshen M, Reges O, et al. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4:e001486.CrossRefGoogle Scholar
  5. 5.
    Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013;34:2746–51.CrossRefGoogle Scholar
  6. 6.
    Deif B, Lowres N, Freedman SB. Screening for atrial fibrillation above age 65 detects an asymptomatic subset at high risk of stroke. Int J Cardiol. 2013;164:371–2.CrossRefGoogle Scholar
  7. 7.
    Rahman F, Kwan GF, Benjamin EJ. Global epidemiology of atrial fibrillation. Nat Rev Cardiol. 2016;13:501.CrossRefGoogle Scholar
  8. 8.
    Freedman B, Potpara TS, Lip GY. Stroke prevention in atrial fibrillation. Lancet. 2016;388:806–17.CrossRefGoogle Scholar
  9. 9.
    Stewart S, Murphy NF, Walker A, et al. Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. Heart. 2004;90:286–92.CrossRefGoogle Scholar
  10. 10.
    Lundqvist CB, Lip GYH, Kirchhof P. What are the costs of atrial fibrillation? Europace. 2011;13:Ii9–12.Google Scholar
  11. 11.
    Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol. 2008;18:209–16.CrossRefGoogle Scholar
  12. 12.
    Tse HF, Wang YJ, Ahmed Ai-Abdullah M, et al. Stroke prevention in atrial fibrillation—an Asian stroke perspective. Heart Rhythm. 2013;10:1082–8.CrossRefGoogle Scholar
  13. 13.
    Institute for Health Metrics and Evaluation. GBD compare [online]. 2013. http://viz.healthmetricsandevaluation.org/gbd-compare/.
  14. 14.
    Sriharibabu M, Himabindu Y, Kabir Z. Rheumatic heart disease in rural south India: a clinico-observational study. J Cardiovasc Dis Res. 2013;4:25–9.CrossRefGoogle Scholar
  15. 15.
    Cheng TO. How much of the recent decline in rheumatic heart disease in China can be explained by changes in cardiovascular risk factors? Int J Cardiol. 2009;132:300–2.CrossRefGoogle Scholar
  16. 16.
    GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390:1151–210.CrossRefGoogle Scholar
  17. 17.
    Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893–962.CrossRefGoogle Scholar
  18. 18.
    Chiang CE, Naditch-Brule L, Murin J, et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ Arrhythm Electrophysiol. 2012;5:632–9.CrossRefGoogle Scholar
  19. 19.
    Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018–22.CrossRefGoogle Scholar
  20. 20.
    d’Arcy JL, Prendergast BD, Chambers JB, et al. Valvular heart disease: the next cardiac epidemic. Heart. 2011;97:91–3.CrossRefGoogle Scholar
  21. 21.
    Zuhlke LJ, Steer AC. Estimates of the global burden of rheumatic heart disease. Glob Heart. 2013;8:189–95.CrossRefGoogle Scholar
  22. 22.
    Shahid Gangalal National Heart Centre. Annual report 2008. Bansbari, Kathmandu: Shahid Gangalal National Heart Centre (SGNHC). http://www.sgnhc.org.np/report-2007/main%20Page%201%20to%2066.pdf.
  23. 23.
    Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coll Cardiol. 2008;52:865–8.CrossRefGoogle Scholar
  24. 24.
    Zubaid M, Rashed WA, Alsheikh-Ali AA, et al. Gulf survey of atrial fibrillation events (Gulf SAFE): design and baseline characteristics of patients with atrial fibrillation in the Arab Middle East. Circ Cardiovasc Qual Outcomes. 2011;4:477–82.CrossRefGoogle Scholar
  25. 25.
    Oldgren J, Healey JS, Ezekowitz M, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation. 2014;129:1568–76.CrossRefGoogle Scholar
  26. 26.
    Ntep-Gweth M, Zimmermann M, Meiltz A, et al. Atrial fibrillation in Africa: clinical characteristics, prognosis, and adherence to guidelines in Cameroon. Europace. 2010;12:482–7.CrossRefGoogle Scholar
  27. 27.
    Bhardwaj R. Atrial fibrillation in a tertiary care institute—a prospective study. Indian Heart J. 2012;64:476–8.CrossRefGoogle Scholar
  28. 28.
    Hersi A, Abdul-Moneim M, Almous’ad A, et al. Saudi atrial fibrillation survey: national, observational, cross-sectional survey evaluating atrial fibrillation management and the cardiovascular risk profile of patients with atrial fibrillation. Angiology. 2015;66:244–8.CrossRefGoogle Scholar
  29. 29.
    Wang DR, Liu M, Lin S, et al. Stroke and rheumatic heart disease: a systematic review of observational studies. Clin Neurol Neurosurg. 2013;115:1575–82.CrossRefGoogle Scholar
  30. 30.
    Singh PIPK, Carapetis JR, Buadromo EM, et al. The high burden of rheumatic heart disease found on autopsy in Fiji. Cardiol Young. 2008;18:62–9.CrossRefGoogle Scholar
  31. 31.
    Marijon E, Ou P, Celermajer DS, et al. Prevalence of rheumatic heart disease detected by echocardiographic screening. N Engl J Med. 2007;357:470–6.CrossRefGoogle Scholar
  32. 32.
    Marascio G, Modesti PA. Current trends and perspectives for automated screening of cardiac murmurs. Heart Asia. 2013;5:213–8.CrossRefGoogle Scholar
  33. 33.
    Perez MV, Wang PJ, Larson JC, et al. Risk factors for atrial fibrillation and their population burden in postmenopausal women: the Women’s Health Initiative Observational Study. Heart. 2013;99:1173–8.CrossRefGoogle Scholar
  34. 34.
    Gillott RG, Willan K, Kain K, et al. South Asian ethnicity is associated with a lower prevalence of atrial fibrillation despite greater prevalence of established risk factors: a population-based study in Bradford Metropolitan District. Europace. 2017;19:356–63.PubMedGoogle Scholar
  35. 35.
    Koopman JJ, van Bodegom D, Westendorp RG, et al. Scarcity of atrial fibrillation in a traditional African population: a community-based study. BMC Cardiovasc Disord. 2014;14:87.CrossRefGoogle Scholar
  36. 36.
    Guo Y, Tian Y, Wang H, et al. Prevalence, incidence, and lifetime risk of atrial fibrillation in China: new insights into the global burden of atrial fibrillation. Chest. 2015;147:109–19.CrossRefGoogle Scholar
  37. 37.
    Amponsah MK, Benjamin EJ, Magnani JW. Atrial fibrillation and race—a contemporary review. Curr Cardiovasc Risk Rep. 2013;7.CrossRefGoogle Scholar
  38. 38.
    Soliman EZ, Alonso A, Goff DC Jr. Atrial fibrillation and ethnicity: the known, the unknown and the paradox. Futur Cardiol. 2009;5:547–56.CrossRefGoogle Scholar
  39. 39.
    Shen AYJ, Contreras R, Sobnosky S, et al. Racial/ethnic differences in the prevalence of atrial fibrillation among older adults—a cross-sectional study. J Nat Med Assoc. 2010;102:906–13.CrossRefGoogle Scholar
  40. 40.
    Dewland TA, Olgin JE, Vittinghoff E, et al. Incident atrial fibrillation among asians, hispanics, blacks, and whites. Circulation. 2013;128:2470–7.CrossRefGoogle Scholar
  41. 41.
    Sacco RL, Kargman DE, Zamanillo M. Race-ethnic differences in stroke risk-factors among hospitalized-patients with cerebral infarction—the Northern Manhattan Stroke Study. Neurology. 1995;45:659–63.CrossRefGoogle Scholar
  42. 42.
    Borzecki AM, Bridgers DK, Liebschutz JM, et al. Racial differences in the prevalence of atrial fibrillation among males. J Nat Med Assoc. 2008;100:237–45.CrossRefGoogle Scholar
  43. 43.
    Lip GY, Golding DJ, Nazir M, et al. A survey of atrial fibrillation in general practice: the West Birmingham Atrial Fibrillation Project. Br J Gen Pract. 1997;47:285–9.PubMedPubMedCentralGoogle Scholar
  44. 44.
    Lip GYH, Bawden L, Hodson R, et al. Atrial fibrillation amongst the Indo-Asian general practice population the West Birmingham Atrial Fibrillation Project. Int J Cardiol. 1998;65:187–92.CrossRefGoogle Scholar
  45. 45.
    Gill PS, Calvert M, Davis R, et al. Prevalence of heart failure and atrial fibrillation in minority ethnic subjects: the Ethnic-Echocardiographic Heart of England Screening Study (E-ECHOES). PLoS One. 2011;6:e26710.CrossRefGoogle Scholar
  46. 46.
    Wandell P, Carlsson AC, Li XJ, et al. Atrial fibrillation in immigrant groups: a cohort study of all adults 45 years of age and older in Sweden. Eur J Epidemiol. 2017;32:785–96.CrossRefGoogle Scholar
  47. 47.
    Modesti PA, Colella A, Zhao D. Atrial fibrillation in first generation Chinese migrants living in Europe: a proof of concept study. Int J Cardiol. 2016;215:269–72.CrossRefGoogle Scholar
  48. 48.
    Sun H, Zou X, Liu L. Epidemiological factors of stroke: a survey of the current status in China. J Stroke. 2013;15:109–14.CrossRefGoogle Scholar
  49. 49.
    Chao TF, Liu CJ, Wang KL, et al. Using the CHA(2)DS(2)-VASc score for refining stroke risk stratification in ‘Low-Risk’ Asian patients with atrial fibrillation. J Am Coll Cardiol. 2014;64:1658–65.CrossRefGoogle Scholar
  50. 50.
    Siu CW. One more “C” for CHA2DS2-VASc score? J Am Coll Cardiol. 2015;65:1602–3.CrossRefGoogle Scholar
  51. 51.
    Lip GYH, Rathore VS, Katira R, et al. Do Indo-Asians have smaller coronary arteries? Postgrad Med J. 1999;75:463–6.CrossRefGoogle Scholar
  52. 52.
    Ackerman MJ, Splawski I, Makielski JC, et al. Spectrum and prevalence of cardiac sodium channel variants among black, white, Asian, and Hispanic individuals: implications for arrhythmogenic susceptibility and Brugada/long QT syndrome genetic testing. Heart Rhythm. 2004;1:600–7.CrossRefGoogle Scholar
  53. 53.
    Tayebjee MH, Lip GYH, Blann AD, et al. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and-9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and-2. Thromb Res. 2005;115:205–10.CrossRefGoogle Scholar
  54. 54.
    Zain SM, Mohamed Z, Mahadeva S, et al. Susceptibility and gene interaction study of the angiotensin II type 1 receptor (AGTR1) gene polymorphisms with non-alcoholic fatty liver disease in a multi-ethnic population. PLoS One. 2013;8:e58538.CrossRefGoogle Scholar
  55. 55.
    Huang H, Darbar D. Genetic heterogeneity of atrial fibrillation susceptibility loci across racial or ethnic groups. Eur Heart J. 2017;38:2595–8.CrossRefGoogle Scholar
  56. 56.
    Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007;448:353–7.CrossRefGoogle Scholar
  57. 57.
    Benjamin EJ, Rice KM, Arking DE, et al. Variants in ZFHX3 are associated with atrial fibrillation in individuals of European ancestry. Nat Genet. 2009;41:879–81.CrossRefGoogle Scholar
  58. 58.
    Ellinor PT, Lunetta KL, Albert CM, et al. Meta-analysis identifies six new susceptibility loci for atrial fibrillation. Nat Genet. 2012;44:670–88.CrossRefGoogle Scholar
  59. 59.
    Gudbjartsson DF, Holm H, Gretarsdottir S, et al. A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke. Nat Genet. 2009;41:876–8.CrossRefGoogle Scholar
  60. 60.
    Sinner MF, Tucker NR, Lunetta KL, et al. Integrating genetic, transcriptional, and functional analyses to identify 5 novel genes for atrial fibrillation. Circulation. 2014;130:1225–35.CrossRefGoogle Scholar
  61. 61.
    Ma JF, Yang F, Mahida SN, et al. TBX5 mutations contribute to early-onset atrial fibrillation in Chinese and Caucasians. Cardiovasc Res. 2016;109:442–50.CrossRefGoogle Scholar
  62. 62.
    Song K, Nam YJ, Luo X, et al. Heart repair by reprogramming non-myocytes with cardiac transcription factors. Nature. 2012;485:599–604.CrossRefGoogle Scholar
  63. 63.
    Lee JY, Kim TH, Yang PS, et al. Korean atrial fibrillation network genome-wide association study for early-onset atrial fibrillation identifies novel susceptibility loci. Eur Heart J. 2017;38:2586–94.CrossRefGoogle Scholar
  64. 64.
    Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492–501.CrossRefGoogle Scholar
  65. 65.
    Dang MT, Hambleton J, Kayser SR. The influence of ethnicity on warfarin dosage requirement. Ann Pharmacother. 2005;39:1008–12.CrossRefGoogle Scholar
  66. 66.
    Shen AY, Chen W, Yao JF, et al. Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation. CNS Drugs. 2008;22:815–25.CrossRefGoogle Scholar
  67. 67.
    Shen AYJ, Yao JF, Brar SS, et al. Racial/ethnic differences in ischemic stroke rates and the efficacy of warfarin among patients with atrial fibrillation. Stroke. 2008;39:2736–43.CrossRefGoogle Scholar
  68. 68.
    Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in medicare beneficiaries with atrial fibrillation. Stroke. 2006;37:1070–4.CrossRefGoogle Scholar
  69. 69.
    Ibrahim SA, Kwoh CK, Harper DL, et al. Racial differences in the utilization of oral anticoagulant therapy in heart failure: a study of elderly hospitalized patients. J Gen Intern Med. 2000;15:134–7.CrossRefGoogle Scholar
  70. 70.
    Meschia JF, Merrill P, Soliman EZ, et al. Racial disparities in awareness and treatment of atrial fibrillation: the REasons for Geographic and Racial Differences in Stroke (REGARDS) study. Stroke. 2010;41:581–7.CrossRefGoogle Scholar
  71. 71.
    Christian JB, Lapane KL, Toppa R. Racial disparities in receipt of secondary stroke prevention agents among US nursing home residents. Stroke. 2003;34:310.CrossRefGoogle Scholar
  72. 72.
    Golwala H, Jackson LR II, Simon DN, et al. Racial/ethnic differences in atrial fibrillation symptoms, treatment patterns, and outcomes: insights from Outcomes Registry for Better Informed Treatment for Atrial Fibrillation Registry. Am Heart J. 2016;174:29–36.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Clinical and Experimental MedicineUniversity of FlorenceFirenzeItaly

Personalised recommendations